Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide

George E. Peoples, Peter S. Goedegebuure, Roy Smith, David C. Linehan, Ichiro Yoshino, Timothy J. Eberlein

Research output: Contribution to journalArticlepeer-review

421 Scopus citations

Abstract

The identification of antigenic peptides presented on the tumor cell surface by HLA class I molecules and recognized by tumor-specific cytotoxic T lymphocytes may lead to a peptide vaccine capable of inducing protective cellular immunity. We demonstrate that both HLA-A2-restricted breast and ovarian tumor-specific cytotoxic T lymphocytes recognize shared antigenic peptides. At least one of these peptides is derived from the oncogene product of HER2/neu, which is overexpressed in 30-40% of all breast and ovarian cancers. T cells sensitized against this nine-amino acid sequence demonstrate significant recognition of HLA-A2+, HER2/neu+ tumors. Since 50% of the tumor-cell population is HLA-A2+ and many different tumors express HER2/neu, this peptide may be widely recognized and have many clinical applications.

Original languageEnglish
Pages (from-to)432-436
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume92
Issue number2
DOIs
StatePublished - Jan 17 1995

Fingerprint

Dive into the research topics of 'Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide'. Together they form a unique fingerprint.

Cite this